FARN:LON
Faron Pharmaceuticals Oy
GBX 36.60
arrow_upward
+0.27%(+0.100) 1D
Oct 12, 3:03:51 PM GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FARN...
Open
GBX 35.06
High
GBX 38.00
Low
GBX 35.00
Mkt. cap
74.16M
Avg. vol.
42.63K
Volume
7.06K
52-wk high
GBX 193.58
52-wk low
GBX 34.00
EPS
-GBX 0.10
Shares outstanding
31.03M
No. of employees
36
Open
GBX 35.06
High
GBX 38.00
Low
GBX 35.00
Mkt. cap
74.16M
Avg. vol.
42.63K
Volume
7.06K
52-wk high
GBX 193.58
52-wk low
GBX 34.00
EPS
-GBX 0.10
Shares outstanding
31.03M
No. of employees
36
News stories
From web sources and news partners
FOREX.com
·
27 minutes ago
Dow Jones Forecast: DJIA cautious as oil jumps & earnings loom
Traders Union
·
32 minutes ago
All 11 S&P 500 sectors are projected to post EPS growth, Sonali Basak notes
Quartz
·
31 minutes ago
Wall Street opens mixed ahead of bank earnings, CPI data
24/7 Wall St.
·
33 minutes ago
Stock Market Today: S&P 500 Futures Pause Near Record Highs as Oil Rises Ahead of Bank Earnings
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
About Faron Pharmaceuticals Oy